U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Monday, June 8, 2026 1 min read
Key Takeaway: Pfizer has received FDA approval for an expanded indication of HYMPAVZI, allowing its use in treating hemophilia A or B patients aged 12 and older with inhibitors, as well as pediatric patients aged 6 to 11. This approval aims to provide routine prophylaxis to prevent bleeding episodes, addressing significant medical needs in these populations.
Market Sentiment Analysis
POSITIVE FACTORS
FDA approval expands treatment options for hemophilia A and B patients.
HYMPAVZI is now available for a broader age range, including pediatric patients.
The drug aims to reduce bleeding episodes significantly.
Full Press Release Details
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for HYMPAVZI® (marstacimab-hncq) to include the treatment of patients with hemophilia A or B 12 years and older with inhibitors and pediatric patients (ages 6 to 11 years) with or without inhibitors. HYMPAVZI is now indicated in the U.S. for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patie
Frequently Asked Questions
What is HYMPAVZI approved for?
HYMPAVZI is approved for treating hemophilia A or B in patients aged 12 and older with inhibitors and pediatric patients aged 6 to 11.
What age groups can use HYMPAVZI?
HYMPAVZI is indicated for adults and pediatric patients aged 6 to 11 years.
What is the purpose of HYMPAVZI?
HYMPAVZI is used for routine prophylaxis to prevent or reduce bleeding episodes.
Who approved HYMPAVZI's expanded indication?
The U.S. Food and Drug Administration (FDA) approved the expanded indication for HYMPAVZI.